Genetic principles enabling the creation of bacteria-based therapeutics
GENETICS · 04.11.2026 · 234 (3)
DOI: 10.1093/genetics/iyag235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift GENETICS, online erschienen am 17.09.2026. Verfasst von Ashley B Williams und 5 weiteren Autor:innen. Beteiligte Einrichtung: SiVEC Biotechnologies, Inc, 3185 Rampart Road, Fort Collins, CO 80521, United States. Hauptthemen laut MEDLINE: Genetic Engineering, Bacteria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Trade Advanced Industries Grant Program, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Genetic engineering can transform bacteria (including Salmonella, Escherichia coli, Listeria, and Yersinia) from naturally occurring microbes into programmable therapeutics. Unlike passive platforms, engineered bacteria can localize to defined biological niches, sense environmental cues, regulate programmed activity in situ, interact with host tissues in novel ways, and persist for controlled periods. These properties make bacteria versatile medicines but require genetic control of precision, safety, stability, and activity under clinical conditions. Major design layers include strain or “chassis” selection, attenuation and biocontainment, control of therapeutic activity, targeting and persistence, and genotype-to-phenotype stability during manufacturing and in vivo use. These features also create liabilities, including off-target behavior, unstable expression, and evolutionary loss of function under selection. Progress depends on safe, clinically translatable chassis with integrated, bounded, and durable behaviors. This review examines the genetic design principles and liabilities of bacteria-based therapeutics, approaches used to produce clinical and near-clinical candidates, and the emergence of programmed bacteria delivering complete gene editing systems to therapeutically relevant cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- SiVEC Biotechnologies, Inc, 3185 Rampart Road, Fort Collins, CO 80521, United States.
ORCID-Profile: Thomas M Groseclose
Förderung
- International Trade Advanced Industries Grant Program
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Colorado Office of Economic Development
- NCATS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Williams, A. B., Groseclose, T. M., Holec, S. A. M., Newman, D., Mora, D. S. O., & Linke, L. (2026). Genetic principles enabling the creation of bacteria-based therapeutics. GENETICS, 234(3). https://doi.org/10.1093/genetics/iyag235
Vancouver
Williams AB, Groseclose TM, Holec SAM, Newman D, Mora DSO, Linke L. Genetic principles enabling the creation of bacteria-based therapeutics. GENETICS. 2026;234(3). doi:10.1093/genetics/iyag235
BibTeX
@article{Williams2026,
author = {Williams, Ashley B and Groseclose, Thomas M and Holec, Sara A M and Newman, Darrian and Mora, Darcy S O and Linke, Lyndsey},
title = {Genetic principles enabling the creation of bacteria-based therapeutics},
journal = {GENETICS},
year = {2026},
volume = {234},
number = {3},
doi = {10.1093/genetics/iyag235}
}
EUVIMED